On page 6, line 24, after "TNF-beta," insert -- (SEQ ID NO:14) --

On page 6, line 24, after "LT-alpha," insert -- (SEQ ID NO:15) --

On page 6, line 24, after "CD40L," insert -- (SEQ ID NO:16) --.

On page 6, line 24, after "Apo-1L," insert -- (Seq ID NO:17) --.

On page 41, line 1, delete "Rockville, Maryland" and insert -- Manassas, Virginia --.

On page 50, line 3, delete "Rockville, Maryland" and insert -- Manassas, Virginia --.

On page 66, lines 4-5, delete "12301 Parklawn Drive, Rockville, MD" and insert -- 10801 University Boulevard, Manassas, Virginia --.

In the Claims:

Please cancel without prejudice claims 1-23 and 26-29.

a3

24. (Amended) A method of treating a mammal having cervical cancer, comprising administering to [a] the mammal [diagnosed as having cancer an effective amount of Apo-2 ligand] Apo-2 ligand polypeptide in an amount effective to induce cell death in the mammal's cancer cells.

Please add the following claims:

a4

-- 30. The method of claim 24 wherein radiation therapy or chemotherapy is further administered to the mammal.

31. The method of claim 30 wherein the Apo-2 ligand polypeptide and the chemotherapy are administered concurrently.

32. The method of claim 30 wherein the chemotherapy is selected from the group consisting of Doxorubicin, 5-Fluorouracil, Cytosine arabinoside, Cyclophosphamide, Thiotepa, Busulfan, Cytoxin, Taxol, Methotrexate, Cisplatin, Melphalan, Vinblastine, and Carboplatin.

33. The method of claim 24 wherein the Apo-2 ligand polypeptide is selected from the group:

(a) a polypeptide comprising amino acid residues 114-281 of Figure 1A (SEQ ID NO:1);

(b) a polypeptide comprising a fragment or variant of (a); and

(c) a polypeptide consisting of amino acid residues 114-281 of Figure 1A (SEQ ID NO:1).

34. The method of claim 24 wherein the Apo-2 ligand polypeptide is linked to a nonproteinaceous polymer selected from the group consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene.

35. A method of treating a mammal having bladder cancer, comprising administering to the mammal Apo-2 ligand polypeptide in an amount effective to induce cell death in the mammal's cancer cells.

36. The method of claim 35 wherein radiation therapy or chemotherapy is further administered to the mammal.

37. The method of claim 36 wherein the Apo-2 ligand polypeptide and the chemotherapy are administered concurrently.

38. The method of claim 36 wherein the chemotherapy is selected from the group consisting of Doxorubicin, 5-Fluorouracil, Cytosine arabinoside, Cyclophosphamide, Thiotepa, Busulfan, Cytoxin, Taxol, Methotrexate, Cisplatin, Melphalan, Vinblastine, and Carboplatin.

39. The method of claim 35 wherein the Apo-2 ligand polypeptide is selected from the group:

(a) a polypeptide comprising amino acid residues 114-281 of Figure 1A (SEQ ID NO:1);

(b) a polypeptide comprising a fragment or variant of (a); and

(c) a polypeptide consisting of amino acid residues 114-281 of Figure 1A (SEQ ID NO:1).

40. The method of claim 35 wherein the Apo-2 ligand polypeptide is linked to a nonproteinaceous polymer selected from the group consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene.

41. A method of treating a mammal having neuroblastoma cancer, comprising administering to the mammal Apo-2 ligand polypeptide in an amount effective to induce cell death in the mammal's cancer cells.

42. The method of claim 41 wherein radiation therapy or chemotherapy is further administered to the mammal.

43. The method of claim 42 wherein the Apo-2 ligand polypeptide and the chemotherapy are administered concurrently.

44. The method of claim 42 wherein the chemotherapy is selected from the group consisting of Doxorubicin, 5-Fluorouracil, Cytosine arabinoside, Cyclophosphamide, Thiotepa, Busulfan, Cytoxin, Taxol, Methotrexate, Cisplatin, Melphalan, Vinblastine, and Carboplatin.

45. The method of claim 41 wherein the Apo-2 ligand polypeptide is selected from the group:

(a) a polypeptide comprising amino acid residues 114-281 of Figure 1A (SEQ ID NO:1);

(b) a polypeptide comprising a fragment or variant of (a); and

(c) a polypeptide consisting of amino acid residues 114-281 of Figure 1A (SEQ ID NO:1).

46. The method of claim 41 wherein the Apo-2 ligand polypeptide is linked to a nonproteinaceous polymer selected from the group

G4

consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene.

47. A method of treating a mammal having glioma or glioblastoma cancer, comprising administering to the mammal Apo-2 ligand polypeptide in an amount effective to induce cell death in the mammal's glioma or glioblastoma cells.

48. The method of claim 47 wherein radiation therapy or chemotherapy is further administered to the mammal.

49. The method of claim 48 wherein the Apo-2 ligand polypeptide and the chemotherapy are administered concurrently.

50. The method of claim 48 wherein the chemotherapy is selected from the group consisting of Doxorubicin, 5-Fluorouracil, Cytosine arabinoside, Cyclophosphamide, Thiotepa, Busulfan, Cytoxin, Taxol, Methotrexate, Cisplatin, Melphalan, Vinblastine, and Carboplatin.

51. The method of claim 47 wherein the Apo-2 ligand polypeptide is selected from the group:

(a) a polypeptide comprising amino acid residues 114-281 of Figure 1A (SEQ ID NO:1);

(b) a polypeptide comprising a fragment or variant of (a); and

(c) a polypeptide consisting of amino acid residues 114-281 of Figure 1A (SEQ ID NO:1).

52. The method of claim 47 wherein the Apo-2 ligand polypeptide is linked to a nonproteinaceous polymer selected from the group consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene.